logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11066369 B1

PDFFull Text
Date of Patent:
Jul. 20, 2021

Filed:

Sep. 10, 2019

N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease

Applicant:

Novartis Ag, Basel, CH;

Inventors:

Mihai Azimioara, La Jolla, CA (US);

Bei Chen, San Diego, CA (US);

Robert Epple, Solana Beach, CA (US);

Ayako Honda, Cambridge, MA (US);

Philip Lam, Somerville, MA (US);

Hasnain Ahmed Malik, Boston, MA (US);

Casey Jacob Nelson Mathison, San Diego, CA (US);

True Ngoc Nguyen, San Diego, CA (US);

Victor Ivanovich Nikulin, Carlsbad, CA (US);

Sejal Patel, Lexington, MA (US);

Dean Paul Phillips, San Marcos, CA (US);

Rodrigo A. Rodriguez, San Diego, CA (US);

Baogen Wu, San Diego, CA (US);

Xuefeng Zhu, San Diego, CA (US);

Assignee:

Novartis AG, Basel, CH;

Attorney:

Daniel E. Raymond

Primary Examiner:

John S Kenyon

Int. Cl.
CPC ...
C07D 401/02 (2006.01); C07D 213/76 (2006.01); C07D 401/14 (2006.01); A61K 31/444 (2006.01); C07D 401/12 (2006.01); A61K 31/4545 (2006.01); A61K 31/46 (2006.01); A61K 31/496 (2006.01); A61K 31/4985 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 405/14 (2006.01); C07D 487/04 (2006.01); C07D 487/10 (2006.01); C07D 491/107 (2006.01); C07D 493/08 (2006.01);
U.S. Cl.
CPC ...
C07D 213/76 (2013.01); A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61K 31/46 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 487/04 (2013.01); C07D 487/10 (2013.01); C07D 491/107 (2013.01); C07D 493/08 (2013.01);
Abstract

The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

Find Patent Forward Citations

Loading…